D-二聚体和纤维蛋白原降解产物联合检测对肝脏肿瘤的临床意义

Clinical Significance of D-Dimer and FDP Combined Detection in Different Liver Tumors

目的检测肝脏良性肿瘤、原发性肝癌和肝转移癌患者的D-二聚体(D-D)和纤维蛋白原降解产物(FDP)含量,探讨两者在肝脏肿瘤中的差异及临床意义。方法采用贝克曼AU-480全自动生化分析仪,应用胶乳增强免疫比浊法对16例肝脏良性肿瘤患者、52例原发性肝癌患者、24例肝转移癌患者进行D-D和FDP含量检测。结果肝脏良性肿瘤组、原发性肝癌组、肝转移癌组患者中,血清D-D含量分别为(0.92±0.67)mg/L,(1.43±0.90)mg/L,(2.25±1.00)mg/L,FDP含量分别为(3.38±1.78)mg/L,(6.72±4.57)mg/L,(10.41±8.95)mg/L,组间具有显著性差异(P<0.05或P<0.01);在肝转移癌、原发性肝癌、肝脏良性肿瘤患者中,D-D阳性率分别为31.25%,46.15%,79.17%,FDP阳性率分别为25.00%,42.31%,87.50%,具有显著性差异(P<0.05)。结论监测DD和FDP的活性改变,对于肝脏不同肿瘤的鉴别诊断、治疗及预后判断具有一定的参考价值。

Objective To detect serum D-dimer （D-D） and fibrinogen degradation products （FDP） content levels in benign liver tumor, primary liver cancer and metastasis liver cancer and to investigate their differences in liver tumor and clinical significance. Methods The Beckman AU- 480 automatic biochemical analyzer was adopted to detect D- D and FDP levels by using latexenhanced turbidimetric immunoassay in 16 cases of benign liver tumor,52 cases of primary liver cancer and 24 cases of metastasis liver cancer. The test results were performed the statistical analysis. Results The serum D- D and FDP levels in benign liver tumor,primary liver cancer and metastasis liver cancer were （0.92 ±0. 67）, （1.43 ±0. 90）, （2.25 ± 1.00）mg/L and （3.38± 1.78）, （6.72 ± 4.57）, （ 10.41 ±8.95）mg/L respectively, which showing the statistical differences（ P 〈 0.05, P 〈 0. 005） ; the positive rates of D - D and FDP in metastasis liver cancer, primary liver cancer and benign liver tumor were 31.25% ,46. 15% ,79.17% and 25.00% , 42.31%,87.50% respectively,which showing the statistical differences（ P 〈 0.05）. Conclusion The change of D- D and FDP levels has certain reference value for the differentiation diagnosis,treatment and prognosis judgement in different liver tumors.